The classification of acute inflammatory neuropathies has undergone constant modifications since the original description of the Guillain–Barré Syndrome (GBS) in 1936.1 Several types of inflammatory neuropathies have been described and it remains a matter of debate whether they represent a continuous spectrum of disorders or distinct disease entities.

The diagnosis of GBS is based exclusively on clinical parameters which include ascending muscle weakness, diminished tendon reflexes, a peak of the disease within 4 weeks after symptom onset and exclusion of other causes.2 A subgroup of patients with GBS present with ataxia that cannot be attributed to paralysis or sensory loss.3 This condition has been termed …